TD Cowen on Alkermes (ALKS): 'we view the update as important initial validation beyond sleep disorders'
Tweet Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating and $58.00 price target on Alkermes (NASDAQ: ALKS).The analyst comments "Alkermes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
